Edmonds L D, Layde P M, James L M, Flynt J W, Erickson J D, Oakley G P
Int J Epidemiol. 1981 Sep;10(3):247-52. doi: 10.1093/ije/10.3.247.
As part of its epidemiologic studies of congenital malformations, the Centers for Disease Control (CDC) conducts two birth defects surveillance systems in the United States. The Metropolitan Atlanta Congenital Defects Programme (MACDP) is an intensive surveillance system using several methods to identify infants born with birth defects in the Atlanta area. The Birth Defects Monitoring Programme (BDMP) is a nationwide surveillance system that monitors 1 million births per year, about a third of all births in the U.S. It relies on diagnoses from newborn discharge summaries to ascertain affected infants. The systems were originally designed to detect potential 'epidemics' of birth defects that could occur following the widespread dissemination of new teratogens similar to thalidomide. In addition to monitoring, they have also proved to be useful resources for a variety of studies of the epidemiology of birth defects.
作为其先天性畸形流行病学研究的一部分，美国疾病控制中心（CDC）在美国开展了两个出生缺陷监测系统。大亚特兰大先天性缺陷项目（MACDP）是一个强化监测系统，它使用多种方法来识别亚特兰大地区出生时患有出生缺陷的婴儿。出生缺陷监测项目（BDMP）是一个全国性的监测系统，每年监测100万例出生情况，约占美国所有出生人数的三分之一。它依靠新生儿出院小结中的诊断来确定受影响的婴儿。这些系统最初旨在检测类似于沙利度胺的新型致畸剂广泛传播后可能发生的潜在出生缺陷“流行”情况。除了监测之外，它们还被证明是出生缺陷流行病学各种研究的有用资源。
